Accessibility Menu
Hydration Pharmaceuticals logo

Hydration Pharmaceuticals(ASX) HPC

Market CapA$2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 YearN/A
1 Year-64%
1 Month+0%
A$0.00
+0.00%
+0.00Today
Hydration Pharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 0.002026-08-24
Hydration Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20%AUD 0.012026-08-13
1 month+0%AUD 0.002026-07-16
3 month+0%AUD 0.002026-05-25
Year to date-20%AUD 0.012025-12-29
1 year-63.64%AUD 0.012025-08-22
3 year-89.74%AUD 0.042023-08-23
Since inception-98.82%AUD 0.342021-12-14

Hydration Pharmaceuticals Financials at a Glance

Market Cap

A$2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.69M

Net Income (TTM)

-$219.48K

EPS (TTM)

-A$0.01

P/E Ratio

-0.34

Dividend

A$0.00

Beta (Volatility)

-0.31 (Low)

Price

A$0.00

Volume

0

Open

A$0.00

Previous Close

A$0.00

Daily Range

A$0.00 - A$0.00

52-Week Range

A$0.00 - A$0.02

Estimated Earnings Date

May 23, 2025

HPC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hydration Pharmaceuticals

The Hydration Pharmaceuticals Company Limited specializes in providing a diverse range of healthy hydration remedies, including liquids, tablets, and powders. Established in 2001 and headquartered in San Diego, California, the company distributes its Hydralyte-branded products through retail and e-commerce channels across Australia, the United States, and Canada.

Products and Services
  • Hydralyte-branded hydration solutions in liquid, tablet, and powder forms
  • Products designed for effective rehydration and electrolyte balance
  • Distribution through both traditional retail and online platforms
Growth Outlook
  • Recent quarterly revenue reached USD 963,511, indicating potential for recovery
  • Trailing twelve months (TTM) gross profit margin stands at 32.86%
  • Current ratio of 2.83 suggests strong liquidity position for future investments
Financial Highlights
  • Quarterly revenue increased from USD 1,525,598 to USD 963,511
  • Net income for the latest quarter was USD -1,448,292, reflecting ongoing challenges
  • Cash and cash equivalents totaled USD 1,119,335, providing operational flexibility
The Hydration Pharmaceuticals Company Limited operates in the food distribution sector, focusing on hydration solutions that cater to health-conscious consumers. The company's product offerings are well-positioned to meet the growing demand for effective hydration remedies, particularly in markets like Australia and North America. Despite facing challenges reflected in recent financial results, the company has shown resilience with a notable gross profit margin. The liquidity position, as indicated by the current ratio, suggests that the company is well-equipped to navigate its operational hurdles and pursue growth opportunities. Investors may find the company's strategic focus on hydration products appealing, especially as health and wellness trends continue to gain traction globally. The potential for recovery in revenue and the solid liquidity position could present opportunities for future growth.
AI Generated • Aug 24, 2026

Industry

Personal Products

Sector

Consumer Staples

CEO

Oliver Baker

Headquarters

Melbourne, VIC 3121, AU

HPC Financials

Key Financial Metrics (TTM)

Gross Margin

32.86%

Operating Margin

-127.49%

Net Income Margin

-115.99%

Return on Equity

-139.90%

Return on Capital

-229.32%

Return on Assets

-131.55%

Earnings Yield

-2.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

537.99M

Volume

0

Avg. Volume

295.18K

Financials (TTM)

Gross Profit

$2.44M

Operating Income

-$7.37M

EBITDA

-$9.10M

Operating Cash Flow

-$5.87M

Capital Expenditure

$0.00

Free Cash Flow

-$5.87M

Cash & ST Invst.

$1.12M

Total Debt

$0.00

Hydration Pharmaceuticals Performance Analysis

Hydration Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 13,126,88460.8%
20232023-12-31USD 6,479,474-50.6%
20242024-12-31USD 4,858,921-25.0%
20252025-12-31USD 3,833,249-21.1%
Hydration Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-304.9%
Q42024-12-31-135.5%
Q22025-06-30186.6%
Q42025-12-31-36.8%
Hydration Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.0927.0%
20232023-12-31USD -0.06-31.4%
20242024-12-31USD -0.03-53.8%
20252025-12-31USD -0.01-60.2%
Hydration Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3044.1%
Q42024-12-31288.5%
Q22025-06-30-118.3%
Q42025-12-3115.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$963.51K

-79.7%

Gross Profit

$64.67K

-97.7%

Gross Margin

6.71%

N/A

Market Cap

A$2.15MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$717.33K

N/A

Employees

3

N/A

Net Income

-$1.45M

+68.3%

EBITDA

-$1.51M

-83.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$1.12M

-39.2%

Total Debt

$0.00

-100.0%

Accounts Receivable

$80.11K

-95.4%

Inventory

$874.53K

-63.4%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-1.32%

N/A

Return on Invested Capital

-2.24%

N/A

Free Cash Flow

-$2.14M

+24.2%

Operating Cash Flow

-$2.14M

+24.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TFL.AXTasFoods Limited
A$0.01+0.00%
EVE.AXEVE Health Group Limited
A$0.02+0.00%
ERG.AXEneco Refresh Limited
A$0.01+0.00%
PTL.AXPrestal Holdings Limited
A$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.82-0.03%
BITOProShares Trust - ProShares Bitcoin ETF
$10.60-0.01%
NVDANvidia
$210.58-0.01%
CRECre8 Enterprise
$6.27+1.44%

Questions About HPC

What is the current price of Hydration Pharmaceuticals?

Hydration Pharmaceuticals is trading at A$0.00 per share.

What is the 52-week range for Hydration Pharmaceuticals?

Over the past 52 weeks, Hydration Pharmaceuticals has traded between A$0.00 and A$0.02.

How much debt does Hydration Pharmaceuticals have?

As of the most recent reporting period, Hydration Pharmaceuticals reported total debt of $0.00.

How much cash does Hydration Pharmaceuticals have on hand?

Hydration Pharmaceuticals reported $1.68M in cash and cash equivalents in its most recent financial results.

What is Hydration Pharmaceuticals’s dividend yield?

Hydration Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services